|
|
|
Washington
(H24N). The fact that Cytotec, a drug manufactured by Searle
to treat ulcers, has been used by some women to induce labor or
to abort their pregnancies prompted the company to send health care
providers a letter warning them about the risks of the off-label
use of the drug.
In a letter dated Aug. 23, Searle, based in Skokie, Ill., reminds
providers that Cytotec is contraindicated in pregnant women because
of its potential to induce labor and cause abortion with fatal consequences
for both the fetus and the mother.
The
drug has approval from the Food and Drug Administration (FDA) for
the prevention of ulcers in patients taking nonsteroidal anti-inflammatory
drugs, including aspirin. These drugs can cause gastric ulcers in
vulnerable patients, such as those with a history of ulcers and
the elderly.
"Searle
has become aware of some instances where Cytotec, outside of its
approved indication, was used as a cervical ripening agent prior
to termination of pregnancy, or for induction of labor, in spite
of the specific contraindications to its use during pregnancy,"
wrote Seale in its letter to health care providers.
Although
Searle has not studied the use of Cytotec for the induction of labor
or the termination of pregnancy and has no plans to, reports of
adverse reactions related to off-label use of the drug by pregnant
women have been disturbing. They include maternal or fetal death,
uterine hyperstimulation, rupture or perforation requiring uterine
surgical repair or hysterectomy, amniotic fluid embolism, severe
vaginal bleeding, retained placenta, shock, fetal bradycardia (slowed
heart beat) and pelvic pain.
In
its letter to health care providers, Searle also cautions doctors
about the lack of information available about Cytotec's effect on
children delivered by mothers who have taken the drug to bring on
labor. "The effect of Cytotec on the later growth, development and
functional maturation of the child when Cytotec is used for induction
of labor or cervical ripening has not been established," wrote Searle.
For more information, visit the FDA Web site.
|
|